Lord, Abbett & Co
UTHR icon

Lord, Abbett & Co’s United Therapeutics UTHR Stock Holding History

Lord, Abbett & Co’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$132M Sell
244,323
-5,953
-2% -$3.35M 0.38% 65
2026
Q1 		$148M Sell
250,276
-7,773
-3% -$3.87M 0.48% 52
2025
Q4 		$126M Sell
258,049
-11,023
-4% -$5.13M 0.39% 69
2025
Q3 		$113M Sell
269,072
-4,615
-2% -$1.55M 0.34% 85
2025
Q2 		$78.6M Buy
273,687
+29,766
+12% +$8.9M 0.25% 109
2025
Q1 		$75.2M Buy
243,921
+27,270
+13% +$9.35M 0.27% 105
2024
Q4 		$76.4M Buy
216,651
+14,956
+7% +$5.5M 0.24% 113
2024
Q3 		$72.3M Buy
201,695
+46,170
+30% +$15.6M 0.23% 132
2024
Q2 		$49.5M Buy
+155,525
New +$41.2M 0.16% 163

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Lord, Abbett & Co's UTHR Position: Q2 2026 in Review

Lord, Abbett & Co reduced its United Therapeutics (UTHR) stake by 2.4% in Q2 2026, selling an estimated $3.35M and leaving 244,323 shares worth $132M. The position accounts for 0.38% of the portfolio, ranked #65.

Lord, Abbett & Co first reported a position in UTHR in Q2 2024 and has held it in 9 quarters since. The position peaked at $148M in Q1 2026. 880 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Lord, Abbett & Co held 244,323 shares of United Therapeutics worth $132M as of Q2 2026.
  • Lord, Abbett & Co sold 5,953 United Therapeutics shares in Q2 2026, an estimated $3.35M.
  • United Therapeutics made up 0.38% of Lord, Abbett & Co's portfolio in Q2 2026, its #65 holding.
  • Lord, Abbett & Co first reported a position in United Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • Lord, Abbett & Co's United Therapeutics position peaked at $148M in Q1 2026.
  • 880 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Lord, Abbett & Co's 13F filing for Q2 2026, filed 14 Aug 2026.